Titre : Cystadénocarcinome

Cystadénocarcinome : Questions médicales fréquentes

{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Cystadénocarcinome : Questions médicales les plus fréquentes", "headline": "Cystadénocarcinome : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Cystadénocarcinome : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-01", "dateModified": "2025-03-28", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Cystadénocarcinome" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Tumeurs kystiques, mucineuses et séreuses", "url": "https://questionsmedicales.fr/mesh/D018297", "about": { "@type": "MedicalCondition", "name": "Tumeurs kystiques, mucineuses et séreuses", "code": { "@type": "MedicalCode", "code": "D018297", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.470.590" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Cystadénocarcinome mucineux", "alternateName": "Cystadenocarcinoma, Mucinous", "url": "https://questionsmedicales.fr/mesh/D018282", "about": { "@type": "MedicalCondition", "name": "Cystadénocarcinome mucineux", "code": { "@type": "MedicalCode", "code": "D018282", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.470.590.480.225" } } }, { "@type": "MedicalWebPage", "name": "Cystadénocarcinome papillaire", "alternateName": "Cystadenocarcinoma, Papillary", "url": "https://questionsmedicales.fr/mesh/D018283", "about": { "@type": "MedicalCondition", "name": "Cystadénocarcinome papillaire", "code": { "@type": "MedicalCode", "code": "D018283", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.470.590.480.230" } } }, { "@type": "MedicalWebPage", "name": "Cystadénocarcinome séreux", "alternateName": "Cystadenocarcinoma, Serous", "url": "https://questionsmedicales.fr/mesh/D018284", "about": { "@type": "MedicalCondition", "name": "Cystadénocarcinome séreux", "code": { "@type": "MedicalCode", "code": "D018284", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.470.590.480.240" } } } ], "about": { "@type": "MedicalCondition", "name": "Cystadénocarcinome", "alternateName": "Cystadenocarcinoma", "code": { "@type": "MedicalCode", "code": "D003536", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Hui Liu", "url": "https://questionsmedicales.fr/author/Hui%20Liu", "affiliation": { "@type": "Organization", "name": "Department of Anesthesiology, West China Second Hospital of Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China." } }, { "@type": "Person", "name": "Ao Wang", "url": "https://questionsmedicales.fr/author/Ao%20Wang", "affiliation": { "@type": "Organization", "name": "Department of Gynecology and Obstetrics, West China Second Hospital of Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China." } }, { "@type": "Person", "name": "Yushan Ma", "url": "https://questionsmedicales.fr/author/Yushan%20Ma", "affiliation": { "@type": "Organization", "name": "Department of Anesthesiology, West China Second Hospital of Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China." } }, { "@type": "Person", "name": "Min Sun", "url": "https://questionsmedicales.fr/author/Min%20Sun", "affiliation": { "@type": "Organization", "name": "Department of Pathology, Xiangya Hospital, Central South University Changsha, Hunan, China." } }, { "@type": "Person", "name": "Yoshifumi Iwagami", "url": "https://questionsmedicales.fr/author/Yoshifumi%20Iwagami", "affiliation": { "@type": "Organization", "name": "From the Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A case of pancreatic mucinous cystadenocarcinoma with malignant ascites without recurrence for more than 8 years after surgery.", "datePublished": "2022-05-11", "url": "https://questionsmedicales.fr/article/35546381", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12328-022-01639-z" } }, { "@type": "ScholarlyArticle", "name": "ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1.", "datePublished": "2024-01-11", "url": "https://questionsmedicales.fr/article/38212795", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12967-023-04819-8" } }, { "@type": "ScholarlyArticle", "name": "Identification of bromodomain-containing proteins prognostic value and expression significance based on a genomic landscape analysis of ovarian serous cystadenocarcinoma.", "datePublished": "2022-10-05", "url": "https://questionsmedicales.fr/article/36276071", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fonc.2022.1021558" } }, { "@type": "ScholarlyArticle", "name": "Folate receptor alpha protein expression in ovarian serous cystadenocarcinoma tumors of The Cancer Genome Atlas: exploration beyond single-agent therapy.", "datePublished": "2024-04-14", "url": "https://questionsmedicales.fr/article/38645083", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1101/2024.04.12.24305742" } }, { "@type": "ScholarlyArticle", "name": "Significant Prognostic Factor at Age Cut-off of 73 Years for Advanced Ovarian Serous Cystadenocarcinoma Patients: Insights from Real-World Study.", "datePublished": "2024-02-03", "url": "https://questionsmedicales.fr/article/38332982", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2147/IJWH.S439335" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Tumeurs", "item": "https://questionsmedicales.fr/mesh/D009369" }, { "@type": "ListItem", "position": 3, "name": "Tumeurs par type histologique", "item": "https://questionsmedicales.fr/mesh/D009370" }, { "@type": "ListItem", "position": 4, "name": "Tumeurs épithéliales épidermoïdes et glandulaires", "item": "https://questionsmedicales.fr/mesh/D009375" }, { "@type": "ListItem", "position": 5, "name": "Tumeurs kystiques, mucineuses et séreuses", "item": "https://questionsmedicales.fr/mesh/D018297" }, { "@type": "ListItem", "position": 6, "name": "Cystadénocarcinome", "item": "https://questionsmedicales.fr/mesh/D003536" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Cystadénocarcinome - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Cystadénocarcinome", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-01", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Cystadénocarcinome", "description": "Comment diagnostiquer un cystadénocarcinome ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels marqueurs tumoraux sont associés ?\nLe diagnostic précoce est-il possible ?\nQuelle est l'importance de l'imagerie ?", "url": "https://questionsmedicales.fr/mesh/D003536?page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Cystadénocarcinome", "description": "Quels sont les symptômes courants ?\nLe cystadénocarcinome cause-t-il des nausées ?\nY a-t-il des symptômes spécifiques aux femmes ?\nLes symptômes varient-ils selon l'emplacement ?\nQuand consulter un médecin pour des symptômes ?", "url": "https://questionsmedicales.fr/mesh/D003536?page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Cystadénocarcinome", "description": "Peut-on prévenir le cystadénocarcinome ?\nQuels facteurs de risque sont évitables ?\nLe dépistage précoce aide-t-il ?\nLes antécédents familiaux influencent-ils le risque ?\nY a-t-il des recommandations alimentaires ?", "url": "https://questionsmedicales.fr/mesh/D003536?page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Cystadénocarcinome", "description": "Quels traitements sont disponibles ?\nLa chirurgie est-elle toujours nécessaire ?\nQuels médicaments sont utilisés en chimiothérapie ?\nLa radiothérapie est-elle efficace ?\nY a-t-il des traitements expérimentaux ?", "url": "https://questionsmedicales.fr/mesh/D003536?page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Cystadénocarcinome", "description": "Quelles complications peuvent survenir ?\nLe cystadénocarcinome peut-il récidiver ?\nComment gérer la douleur liée au cancer ?\nY a-t-il des risques liés à la chimiothérapie ?\nLes complications affectent-elles la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D003536?page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Cystadénocarcinome", "description": "Quels sont les principaux facteurs de risque ?\nLe mode de vie influence-t-il le risque ?\nLes hormones jouent-elles un rôle ?\nY a-t-il des prédispositions génétiques ?\nL'exposition à des substances chimiques est-elle un risque ?", "url": "https://questionsmedicales.fr/mesh/D003536?page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer un cystadénocarcinome ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'imagerie, la biopsie et les marqueurs tumoraux." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent l'échographie, le scanner et l'IRM." } }, { "@type": "Question", "name": "Quels marqueurs tumoraux sont associés ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "CA-125 et CA 19-9 sont souvent mesurés pour évaluer le cystadénocarcinome." } }, { "@type": "Question", "name": "Le diagnostic précoce est-il possible ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, mais il est souvent difficile en raison de symptômes non spécifiques." } }, { "@type": "Question", "name": "Quelle est l'importance de l'imagerie ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie aide à localiser la tumeur et à évaluer son extension." } }, { "@type": "Question", "name": "Quels sont les symptômes courants ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent douleur abdominale, ballonnements et perte de poids." } }, { "@type": "Question", "name": "Le cystadénocarcinome cause-t-il des nausées ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les nausées peuvent survenir en raison de la pression sur les organes." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques aux femmes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les femmes peuvent ressentir des douleurs pelviennes et des irrégularités menstruelles." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'emplacement ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes dépendent de la localisation de la tumeur, comme ovarienne ou pancréatique." } }, { "@type": "Question", "name": "Quand consulter un médecin pour des symptômes ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Consultez un médecin si les symptômes persistent ou s'aggravent." } }, { "@type": "Question", "name": "Peut-on prévenir le cystadénocarcinome ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention garantie, mais un suivi régulier est conseillé." } }, { "@type": "Question", "name": "Quels facteurs de risque sont évitables ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le tabagisme et maintenir un poids santé peuvent réduire certains risques." } }, { "@type": "Question", "name": "Le dépistage précoce aide-t-il ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Le dépistage peut aider à détecter des anomalies, mais n'élimine pas le risque." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le risque ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancers peuvent augmenter le risque de cystadénocarcinome." } }, { "@type": "Question", "name": "Y a-t-il des recommandations alimentaires ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et riche en antioxydants peut être bénéfique." } }, { "@type": "Question", "name": "Quels traitements sont disponibles ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la chirurgie, la chimiothérapie et la radiothérapie." } }, { "@type": "Question", "name": "La chirurgie est-elle toujours nécessaire ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La chirurgie est souvent nécessaire pour enlever la tumeur, selon son stade." } }, { "@type": "Question", "name": "Quels médicaments sont utilisés en chimiothérapie ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des agents comme le carboplatine et le paclitaxel sont couramment utilisés." } }, { "@type": "Question", "name": "La radiothérapie est-elle efficace ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La radiothérapie peut être utilisée pour réduire la taille de la tumeur ou soulager la douleur." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des essais cliniques évaluent de nouvelles thérapies ciblées et immunothérapies." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la propagation de la maladie et des douleurs chroniques." } }, { "@type": "Question", "name": "Le cystadénocarcinome peut-il récidiver ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il existe un risque de récidive après traitement, nécessitant un suivi." } }, { "@type": "Question", "name": "Comment gérer la douleur liée au cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des analgésiques et des thérapies complémentaires peuvent aider à gérer la douleur." } }, { "@type": "Question", "name": "Y a-t-il des risques liés à la chimiothérapie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la chimiothérapie peut entraîner des effets secondaires comme la fatigue et les nausées." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement impacter la qualité de vie des patients." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, le sexe féminin et des antécédents familiaux de cancer." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des habitudes comme le tabagisme et l'obésité augmentent le risque." } }, { "@type": "Question", "name": "Les hormones jouent-elles un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des déséquilibres hormonaux peuvent contribuer au développement de tumeurs." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mutations génétiques, comme BRCA1 et BRCA2, augmentent le risque." } }, { "@type": "Question", "name": "L'exposition à des substances chimiques est-elle un risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certains produits chimiques peut augmenter le risque de cancer." } } ] } ] }

Sources (35 au total)

ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1.

Ovarian cancer (OC) is a malignant neoplasm that displays increased vascularization. Angiopoietin-like 4 (ANGPTL4) is a secreted glycoprotein that functions as a regulator of cell metabolism and angio... The expression of ANGPTL4 was confirmed by bioinformatics and IHC in OC. The potential molecular mechanism of ANGPTL4 was measured by RNA-sequence. We used a series of molecular biological experiments... Our study demonstrates a significant upregulation of ANGPTL4 in OC specimens and its strong association with unfavorable prognosis. RNA-seq analysis affirms that ANGPTL4 facilitates OC development by ... Our findings underscore that ANGPTL4 promotes OC development via JAK signaling and induces angiogenesis in the tumor microenvironment through its interaction with ESM1....

Identification of bromodomain-containing proteins prognostic value and expression significance based on a genomic landscape analysis of ovarian serous cystadenocarcinoma.

Ovarian serous cystadenocarcinoma (OSC), a common gynecologic tumor, is characterized by high mortality worldwide. Bromodomain (BRD)-containing proteins are a series of evolutionarily conserved protei... We performed the differential expression, GO enrichment, GSEA, immune infiltration, risk model, subtype classification, stemness feature, DNA alteration, and epigenetic modification analysis for these... Most BRDs were dysregulated in OSC tissues compared to normal ovary tissues. These BRDs were positively correlated with each other in OSC patients. Gene alteration and epigenetic modification were sig... BRDs are potential targets and biomarkers for OSC patients, especially BRPF1....

Folate receptor alpha protein expression in ovarian serous cystadenocarcinoma tumors of The Cancer Genome Atlas: exploration beyond single-agent therapy.

Epithelial ovarian cancer (EOC) can be highly lethal, with limited therapeutic options for patients with non-homologous recombination deficient (HRD) disease. Folate receptor alpha (FOLR1/FRα)-targeti... Epithelial ovarian cancer can be highly lethal, with limited therapeutic options for patients without BRCA mutations or non-homologous recombination deficient disease. Folate receptor alpha (FRα)-targ...

Significant Prognostic Factor at Age Cut-off of 73 Years for Advanced Ovarian Serous Cystadenocarcinoma Patients: Insights from Real-World Study.

The objective of this research was to determine the age cut-off for worse prognosis and investigate age-related differentially expressed genes (DEGs) in patients with advanced ovarian serous cystadeno... In this research, we included a cohort of 20,846 patients diagnosed with AOSC, along with RNA-seq data from 374 patients in publicly available databases. Then we used the X-tile software to determine ... We stratified the patients into young group (n=16,336) and old group (n=4510) based on the cut-off age of 73 years by X-tile software. Age over 73 years was identified as an independent risk factor fo... Our study determined 73 years as the cutoff value for age in patients with AOSC....